US 10858459

I'll search for authoritative records on this patent number, including USPTO/CAFC docket activity.

US 10,858,459 B2 — Analyst Summary

Search scope note: I searched for USPTO/Google Patents records for the exact number 10858459 and separately for litigation/CAFC activity. I found no authoritative record of any district-court case or CAFC appeal involving this patent (see "Litigation" below). I did not find litigation evidence, so I am not asserting there is none — only that nothing surfaced.

---

Bibliographic data (authoritative, from the patent record)

Identifier / naming cautions (literal reading, not auto-corrected):

• The inventor is listed as "Kathy S. Clear" on this document, whereas sibling family members (e.g., US 10,246,528 B2) list "COLLINS, Kathy S." I am treating these as distinct literal identifiers, not assuming they are the same person, though they plausibly reflect a name change.
• One aggregator (unifiedpatents.com) showed a priority date of 2014-01-08, one day off from the 2014-01-09 shown on the patent document itself. I flag this rather than reconcile it.
• US 10,858,459 B2 is a continuation in a family that also includes US 10,246,528 B2 (granted 2019-04-02) and pre-grant pubs US 2015/0191554 A1 and US 2019/0153129 A1.

---

Abstract (as printed)

"Methods for preparing supported chromium catalysts containing a chromium (III) compound and an activator-support are disclosed. These supported chromium catalysts can be used in catalyst compositions for the polymerization of olefins to produce polymers having low levels of long chain branching, and with greater sensitivity to the presence of hydrogen during polymerization."

---

Plain-language overview

This patent covers a way of making an ethylene polymerization catalyst from trivalent chromium — Cr(III) — rather than the conventional hexavalent Cr(VI) ("Phillips-type") chromium. The trick is that the Cr(III) compound (e.g., chromium(III) acetylacetonate, "Cr(AcAc)₃") is combined with an activator-support (a solid oxide such as silica-coated alumina, silica-alumina, or sulfated alumina that has been treated with an electron-withdrawing anion like fluoride or sulfate), and the mixture is then heat-treated in a non-oxidizing atmosphere (nitrogen, argon, vacuum, or reducing gases such as CO or H₂) rather than in air. This lets the Cr(III) be deposited/impregnated onto the support without oxidizing it to Cr(VI), so the conventional high-temperature air calcination step is avoided.

The patent asserts several unexpected results versus Cr(VI) systems: (1) much higher tolerance to organoaluminum co-catalysts (up to ~2 mmol/L TIBA, vs. Cr(VI) systems that can be poisoned at >10 ppm); (2) strong hydrogen sensitivity, allowing melt index to be tuned over a wide range; (3) high molecular weight, broad-MWD polymers with low long-chain branching and short relaxation times; and (4) ability to run alongside a metallocene (dual/bimodal MWD) because the activator-support activates both the Cr and the metallocene Zr.

---

Independent claims — plain language

Important uncertainty caveat: I was not able to retrieve the verbatim granted claim set of US 10,858,459 B2 itself. The claim characterizations below are reconstructed from (a) the sibling/parent pre-grant publication US 2019/0153129 A1 (https://www.freepatentsonline.com/y2019/0153129.html), whose independent claims 1, 9, 13, and 16 correspond directly to this family, and (b) the "Embodiments" section of the US 10,858,459 specification (Embodiments 1, 9, 28, 52, 53, 63, 64), which mirrors the independent-claim set. Treat the numbering as likely correct but unverified for this specific grant.

1. Independent claim 1 — Process for making the supported catalyst. Combine (i) a chromium(III) compound with (ii) an activator-support comprising a solid oxide treated with an electron-withdrawing anion, to form a mixture; then subject that mixture to a non-oxidizing atmosphere at a peak temperature to produce the supported chromium catalyst.

2. Independent claim 9 — Catalyst composition. A supported chromium catalyst comprising (a) a Cr(III) compound (or a derivative of it) and (b) an activator-support comprising a solid oxide treated with an electron-withdrawing anion; plus a co-catalyst (e.g., an organoaluminum such as TIBA or TEA, or an aluminoxane).

3. Independent claim 13 — Olefin polymerization process. Contact the composition of claim 9 with an olefin monomer (optionally a comonomer) in a polymerization reactor system under polymerization conditions to make an olefin polymer.

4. Independent claim 16 — Ethylene polymer product (product-by-properties). An ethylene polymer having: Mw from about 300,000 to about 1,000,000 g/mol; Mw/Mn ≥ about 50; and a relaxation time ≤ about 100 sec.

5. Independent claim (per Embodiment 52/53 grouping) — Polymer/article aspects. The specification also lays out independent-claim-style embodiments directed to (a) an olefin polymer produced by the disclosed polymerization process, (b) an ethylene polymer characterized by Mw/Mn ≥ ~35 together with Mw in ~200,000–2,000,000 g/mol ranges, (c) an article of manufacture comprising such a polymer, and (d) a method of forming an article by polymerizing and then forming (blending, melt processing, extruding, molding, thermoforming) the polymer.

---

Dependent-claim themes (for context)

Peak temperature ranges (e.g., 25–600 °C, 150–350 °C); inert vs. reducing atmosphere; dry-blend/sublimation vs. solvent impregnation; specific Cr(III) carboxylates and 1,3-diketonates; specific solid oxides and electron-withdrawing anions (fluoride/sulfate); Cr loading (0.1–10 wt.%); co-catalyst:Cr molar ratio (10:1–1000:1); activity >500 g/g/h at 100:1 Al:Cr; hydrogen-sensitivity limitations; reactor types; and comonomer/distribution limitations (conventional comonomer distribution, SCB at Mn > SCB at Mw/Mz).

---

Litigation / CAFC docket check

• Searches for a CAFC 2026 docket or any infringement action naming 10858459 returned no results. I have no authoritative confirmation of any litigation or appeal. If you need a definitive negative, verify directly against PACER/Docket Navigator and the CAFC docket; I cannot confirm absence from search alone.

Verification links

• Patent text: https://patents.google.com/patent/US10858459B2/en
• Pre-grant pub (family, with claims): https://www.freepatentsonline.com/y2019/0153129.html
• Sibling grant US 10,246,528 B2: https://pubchem.ncbi.nlm.nih.gov/patent/US-[10246528](/patent/10246528)-B2

I'll search litigation databases and other sources for this specific patent number.

Search Results: Litigation Involving U.S. Patent No. 10,858,459

Summary: I found no litigation (district court, ITC, or PTAB) involving U.S. Patent No. 10,858,459 ("Chromium (III) catalyst systems with activator-supports," Chevron Phillips Chemical Co. LP).

Searches of litigation-oriented sources — including Unified Patents' litigation caselist coverage, general web searches on the patent number (bare and comma-formatted), and targeted searches pairing the patent title/assignee with "lawsuit," "infringement," "litigation," and "PTAB" — returned no cases naming this patent. Note that a search restricted strictly to the exact number is important here, since Chemours/CPChem polyolefin catalyst patents share similar subject matter and numbers (e.g., the related Univation "Polyolefin Production With Chromium-Based Catalysts" EPO opposition I encountered concerns a different patent, not US 10,858,459).

Case-by-case table

There are no cases to enumerate.

Important caveats on my confidence

I want to be explicit rather than imply more certainty than I have:

• Search coverage limits. I could not directly query PACER (paid, and not accessible here), the ITC EDIS system, or Docket Navigator/Lex Machina. My results come from general web indices and secondary litigation-tracking sources (e.g., Unified Patents-style aggregators). These may lag or may not surface a very recent complaint, nor a case where the patent is asserted but the number is referenced only in an exhibit or claim chart.
• This patent's likely assertion posture (analysis, not finding). US 10,858,459 issued 2020-12-08 from Appl. No. 16/839,154, filed 2020-04-03, with a priority date of 2014-01-09 and an anticipated expiration of 2034-01-09 (per the Google Patents record). It is a Chevron Phillips Chemical Co. LP patent directed to Cr(III)/activator-support catalyst systems. Chevron Phillips has historically been a defensive/first-party player in this space (it appears frequently as a patent opponent at the EPO and as a target of others' oppositions) rather than a prolific district-court plaintiff on chromium catalyst patents. That makes a finding of "no litigation" plausible — but that is my inference, not a documented fact.
• Related activity I did observe (not litigation of this patent). Secondary sources list EPO oppositions and PTAB filings in the broader Chevron Phillips / polyolefin-catalyst arena (e.g., an opposition citing a Univation "Polyolefin Production With Chromium-Based Catalysts" patent, Nov. 15, 2021). These concern different patents and should not be attributed to US 10,858,459.

Recommendation to confirm as of your date (April 26, 2026)

To verify the negative result with higher confidence than open-web searching allows, I suggest checking directly:

1. PACER (CourtListener's RECAP or Docket Navigator) for "10,858,459" across all district courts.
2. USPTO PTAB (IPR/PGR/CBM/Derivation) via the PTAB Endpoint or Patent Public Search for this patent number.
3. USITC EDIS for any Section 337 complaint naming the patent.
4. Unified Patents Patents Litigation caselist — filtered to this exact number.
5. The USPTO Patent Assignment / PatentCenter file history, which sometimes contains litigation-related certificates of correction or § 298 notices.

If you'd like, I can draft the exact search strings/URLs for those databases so you (or a paralegal with PACER access) can run the confirmatory check.

Proceedings overview

Total AIA trial proceedings on US 10,858,459: 0. The structured "PTAB proceedings on file" block — sourced from the USPTO Open Data Portal, the canonical list — returns no AIA trial proceedings for this patent, and my independent web searches (Google Patents/PTAB decision indices, CourtListener-style aggregators, and Unified Patents' patent portal) surfaced no IPR, PGR, or CBM naming US 10,858,459 as the challenged patent. There is nothing to break down by status: no instituted trials, no final written decisions, no invalidated or sustained claims, no settlements, no institution denials, and (necessarily) no Federal Circuit appeals arising from a PTAB FWD on this patent.

The bottom line for a defendant: the patent is untested at the PTAB, not "hardened" by survival. This is emphatically not the "claims 1-5 have been canceled" scenario — every claim remains live and presumptively valid under § 282. Because no petitioner has ever run the IPR gauntlet against this particular patent, there is no PTAB record to borrow, no claim-construction ruling to exploit, and no estoppel on the other side. Conversely, there is also no patent-owner-favorable PTAB win signaling that the claims are unusually robust — this patent simply has not been litigated at the Board.

No proceedings to report

There is no proceeding number, petitioner, panel, institution decision, final written decision, settlement, or appeal to describe. I will not invent one. The absence of PTAB activity is a real data point, and I flag it as such rather than filling the template with placeholder sections.

One caution on identifier hygiene: web searches for this patent number return a superficially similar string from an unrelated matter — a pending IPR petition against US 10,585,959 (a search/software patent, see the docket entry for Google LLC v. AccuSearch Technologies LLC, IPR2026-00286, filed 2026-03-06). That is a different patent with a transposed digit pattern, not a proceeding on the '459 patent. Do not let that citation migrate into a brief.

---

Strategic summary

Claim status. All claims of US 10,858,459 are UNTESTED before the PTAB. None are canceled, none are statutorily disclaimed (the face of the patent shows a terminal disclaimer, which is a common-ownership/prosecution tool, not a claim cancellation), and none have been confirmed by the Board. The asserted estate is therefore the full issued set — the claims are those recited in the patent as granted on 2020-12-08, with an anticipated expiration of 2034-01-09 (as reflected in the ODP legal-status data; the patent claims priority to 2014-01-09 and arose as a continuation of US 10,662,266, itself a division of US 10,246,528).

Estoppel landscape. § 315(e)(2) estoppel is a non-issue here because no IPR has ever been instituted on this patent — there is no petitioner, no real party in interest, and no privy subject to estoppel. For a defendant being asserted against today, the entire prior-art field is open: § 102 and § 103 grounds built on any reference, printed publication, or public use predating the 2014-01-09 priority date, whether or not it appears anywhere in the patent's cited-art list, remain available in an IPR petition. The only practical gates are the § 315(b) one-year bar running from service of a complaint alleging infringement, and the § 311(b) limitation to patents and printed publications.

Pattern signals. The patent owner is Chevron Phillips Chemical Company LP — a large operating chemical company, not an NPE or a troll, which materially changes the defensive calculus: this is a portfolio patent in a competitive polyethylene-catalyst field, and IPR respondents would be competitor producers rather than a defensive aggregator. Unified Patents' portal lists US-10858459-B2 in its database but there is no Unified-filed challenge on record; its presence there reflects crawler-indexed data, not a filing. Chevron Phillips has historically been more active as a patent owner in litigation and licensing than as a serial IPR petitioner. I found no evidence that any party has sought PTAB review of this patent or of its two family siblings, US 10,246,528 and US 10,662,266 — so the entire Cr(III)/activator-support family appears untouched at the Board. The absence of a family-wide attack is itself mildly notable: this is a commercially meaningful catalyst family, and the lack of IPRs suggests either limited assertion activity or targets who have chosen district-court invalidity rather than PTAB routes.

---

Recommended next steps

• No PTAB activity exists on US 10,858,459 — say so plainly and plan accordingly. There is no FWD to link to, no canceled claim to cite, and no Board ruling to quote. Any argument that "the claims have already been invalidated" would be false.
• Petition posture. If a § 337 ITC action or district-court complaint has been served on you, calendar the § 315(b) one-year bar from the service date immediately; that is the hard deadline for filing. Note that the patent is a continuation of US 10,662,266 and a division of US 10,246,528, so confirm which family member is actually being asserted — a challenge must be aimed at the specific claims of the specific patent in suit, and a family-wide strategy may require more than one petition (subject to the Board's discretionary-denial practice under General Plastic / Fintiv-style considerations, and to the current § 325(d) framework).
• Claim-scope work first. Because the Board has never construed these claims, the highest-value pre-petition step is your own claim-construction analysis of claim 1 (the process claim reciting combining a chromium (III) compound with an electron-withdrawing-anion-treated solid oxide and subjecting the mixture to a non-oxidizing atmosphere at a peak temperature) and of the composition claims (claim 9) and polymerization-process claims (claim 13). The specification's broad peak-temperature ranges (0–600 °C; 25–600 °C; 150–350 °C) and the "about" language throughout are the natural § 112 and § 103 battlegrounds.
• Watch the docket, not the aggregators. If activity materializes, the milestones to track are: petition filing → PO preliminary response (3 months) → institution decision at 6 months → statutory FWD deadline at 12 months from institution (§ 316(a)(11), extendable up to 6 months for good cause). Monitor via USPTO PTAB E2E / Patent Center for this patent's application number 16/839,154, and CourtListener / the Federal Circuit docket for any appeal arising from a future FWD.
• Verify independently before relying on this. The ODP ingest is a snapshot; I searched for proceedings the API might not have indexed and found none. Re-run the check against PTAB E2E before relying on this in a filing or an opinion letter.

Confidence note: I have high confidence in the "zero proceedings" conclusion based on the ODP structured data plus the searches run today (2026-09-12). I could not locate any PTAB proceeding, FWD, settlement, or CAFC appeal on this patent, and I am explicitly declining to supply proceeding numbers, panels, or dispositions that do not exist.

I'll start by attempting to pull the actual assignment records rather than guessing at them.

Let me make one more targeted pass for the actual recordation data (reel/frame) before writing up.

Ownership & Assignment Reconstruction — US 10,858,459 B2

Data-availability caveat (read first): I could not retrieve the reel/frame numbers or the recorded correspondent for this patent. The USPTO Assignment Center is an interactive, session-based search that is not reachable through the tools available to me, and the patent-assignment records for this patent were not surfaced by any of the third-party indexes I queried (Google Patents legal events, Plainsite, Unified Patents, FreePatentsOnline). Everything below that is not sourced is marked as unverified. I have deliberately not guessed at reel/frame numbers — a fabricated reel/frame is worse than a documented gap.

---

Inventors

Unusual-pattern check: No evidence of inventors departing CPChem within 12 months of filing. All three are career CPChem/Phillips catalyst researchers, and McDaniel continued filing CPChem applications well after this family (e.g., the September 2019-executed assignment recorded at Reel 64368/592 for "Modified Supported Chromium Catalysts," U.S. Pat. 11,376,575). No fire-sale precursor pattern.

---

Original assignee

Chevron Phillips Chemical Company LP — named on the face of the issued patent and listed as current assignee (Google Patents bibliographic record for US 10,858,459 B2). Address of record: 10001 Six Pines Drive, The Woodlands, TX 77380 (also recorded at 2613 Camino Ramon, San Ramon, CA 94583 in a related CPChem assignment, Reel 64368/592).

• Products embodying the claims: Yes. CPChem is a major producer of chromium-based polyethylene catalysts and HDPE resins; the patent's own FIG. 2 compares the Example 5 resin against three commercial Cr(VI) resins, one of which is a CPChem Marlex™ grade (BHB5003, used as the GPC standard in the specification). CPChem also licenses loop-slurry/Cr-catalyst technology — the First Court of Appeals opinion in Ineos v. Chevron Phillips (No. 01-09-00504-CV, Dec. 17, 2009) documents "over 100 licensing agreements" for the loop slurry process.
• Primary line of business: Petrochemicals — olefins, polyolefins, alpha-olefins, aromatics. A 50/50 joint venture of Chevron Corporation and Phillips 66.
• Current status: Operating. No bankruptcy, no dissolution. Active patent plaintiff/enforcer historically (trade-secret and patent litigation against Ineos; 18 oppositions filed and 45 faced per GreyB's IP Verse competitive analysis).
• Note, not a finding: If the chromium-Cr(III) catalyst claims read onto CPChem's own commercial HDPE production, this is an operating company asserting/holding in its own field — the opposite of an NPE posture.

---

Assignment timeline

One (1) post-filing assignment record is visible in the primary sources. All other gaps are flagged.

• 2020-04-06 (recorded; execution date not disclosed in available sources) — Reel/Frame not retrievable; see caveat above
  • Conveyance: Assignment of Assignors' Interest (USPTO conveyance code 23)
  • Assignor: Clear, Kathy S.; McDaniel, Max P.; Hlavinka, Mark L. (all three named inventors, jointly)
  • Assignee: Chevron Phillips Chemical Company LP
  • Correspondent: Not retrievable. No correspondent of record surfaced; no repeat-player NPE-adjacent attorney appears anywhere in this chain. CPChem's foreign filings show a corporate IP department ("Company SMAS Intellectual Property," Egyptian Patent Gazette) rather than an outside boutique — consistent with routine in-house-drafted inventor assignments, but I cannot confirm the US correspondent.
  • Context: Routine inventor-to-employer confirmation of title on a newly filed continuation (application 16/839,154, filed 2020-04-03 — three days before recordation). Not an acquisition, not a fire-sale, not a transfer to an asserter.
  • Source: Google Patents legal-events entry: "2020-04-06 Assigned to CHEVRON PHILLIPS CHEMICAL COMPANY LP — ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLEAR, Kathy S., MCDANIEL, MAX P., HLAVINKA, MARK L."

No subsequent assignment, security agreement, merger, change of name, or release is recorded or visible for this patent. On the available record the chain terminates at the original operating-company assignee.

Family context (relevant to why a 2020 continuation exists, but not itself an assignment): priority date 2014-01-09; sibling patent US 10,662,266 B2 ("Chromium (III) catalyst systems with activator-supports") issued 2020-05-26 to the same assignee; the 10,858,459 application was filed 2020-04-03 as a continuation in that family and granted 2020-12-08. Anticipated expiration: 2034-01-09.

---

Timeline diagram

timeline
    title Ownership of US 10858459
    2014 : Priority application filed 09 Jan
    2020 : Continuation filed 03 Apr
         : Inventors assign to Chevron Phillips
         : Sibling patent 10662266 granted
         : Patent 10858459 granted 08 Dec
    2034 : Anticipated expiration 09 Jan

---

NPE / troll-pattern signals

---

Verdict

Insufficient data (per the rubric: only the original assignment)

Justification. The record contains exactly one assignment — the three inventors' conveyance of rights to Chevron Phillips Chemical Company LP, recorded 2020-04-06 against application 16/839,154 — and no reel/frame or correspondent was retrievable through my sources, so I cannot complete the chain of record with the specificity required. Applying the literal rubric ("no records, or only the original assignment → Insufficient data"), that is the correct call. It is important not to misread this as ambiguity about NPE status: all eight NPE signals are affirmatively not present, and the assignee of record is a $15B-revenue-range petrochemical manufacturer whose products practice the disclosed chromium-catalyst chemistry and which litigates in its own name rather than through an assertion vehicle. If the question is narrowed to "is this patent NPE-controlled or NPE-asserted?" the evidence-based answer is no.

Verification links. Search the patent number at the USPTO Assignment Center — https://assignmentcenter.uspto.gov/ — or the legacy interface at https://assignment.uspto.gov/patent/index.html. A manual session-based lookup by patent number 10858459 (and by application 16/839,154, and by assignor name "Collins, Kathy S." as well as "Clear, Kathy S.") is required to fill in the reel/frame, execution date, and correspondent that I could not obtain. Cross-check U.S. Pat. 10,662,266 B2, which shares the 2014-01-09 priority date and the same assignee.

---

Two open items I am flagging rather than resolving:

1. The missing reel/frame and correspondent. This is the single largest gap; without the correspondent of record I cannot complete signal #3 to the standard the task demands.
2. The "Clear" vs. "Collins" inventor name variant. Anyone running this assignment search should query both names; a search on the issued-patent spelling alone may under-return.

I'll pull the actual cited-reference (front-page) data for US 10,858,459 rather than relying on memory, then map each reference to the claims.

Good — I have the front-page U.S. citation list. Now let me pull the complete cited-reference set (U.S., foreign, and non-patent literature) from the patent's own record.

Let me get the remainder of the citation list (foreign documents and non-patent literature) and the "cited by" set.

Prior-Art Analysis — U.S. Patent No. 10,858,459 B2

Source and method (read first)

I retrieved the front-page "(56) References Cited" list as it is printed on the granted patent itself, from the issued PDF: https://patentimages.storage.googleapis.com/b4/1b/f5/746c82f45e9a79/US10858459.pdf, cross-checked against the Justia record (https://patents.justia.com/patent/10858459) and the PubChem family record for the sibling grant US 10,246,528 B2 (https://pubchem.ncbi.nlm.nih.gov/patent/US-10246528-B2).

Three limits you must carry through this memo:

1. The "(56)" list I recovered is incomplete at the tail end and the "Other Publications" (non-patent literature) sub-block was not retrieved in full. The U.S. sub-list I confirmed runs from US 2,951,816 through US 7,884,163 and then truncates; the foreign sub-list is partly recovered. I have not invented the missing entries.
2. The verbatim granted claim set of US 10,858,459 was still not retrievable in this pass — consistent with the flag already raised in the earlier Obviousness section. Claim mapping below therefore uses the family claim architecture (process / composition+co-catalyst / polymerization process / product-by-properties) already documented in the Patent Summary section, at the issue count of 26 claims.
3. The front page is an examiner/applicant citation list, not a § 102 rejection. A reference appearing there is not thereby an anticipating reference. Several entries are cited purely for reactor geometry, GPC methodology, or co-catalyst genera.

Legal framework applied: the '459 patent claims priority to 2014-01-09, so AIA § 102 governs (effective filing after 16 March 2013). Anticipation therefore requires the reference to be § 102(a)(1) art (patented/published before the effective filing date) and to disclose every claimed element arranged as claimed. All references below predate 2014 by decades, so the date gate is satisfied for all of them; the analysis turns entirely on the element-by-element gate. I also flag that if the '459 were ever held not entitled to the 2014-01-09 priority (its own filing is 2020-04-03), the critical date shifts forward to 2020-04-03 and every reference below still remains § 102(a)(1) art — the conclusion is priority-date-invariant.

---

Bottom line up front

No reference cited on the face of US 10,858,459 anticipates any claim of the patent.

Every claim in the family requires the concurrence of (a) a chromium (III) compound — i.e. trivalent, chelate/carboxylate, carbon-containing — and (b) an activator-support defined as a solid oxide treated with an electron-withdrawing anion, plus (for the composition claims) a co-catalyst. The cited art splits cleanly into two camps that never overlap on the face of a single reference:

• Camp A — Cr(III)/Cr chelate on an untreated inorganic oxide, treated in a non-oxidizing atmosphere. This camp supplies element (a) and the non-oxidizing heat-treatment step, but on plain silica/alumina/aluminophosphate, never on an electron-withdrawing-anion-treated activator-support.
• Camp B — activator-supports (fluorided/sulfated solid oxides, silica-coated alumina). This camp supplies element (b), but in the context of Cr(VI) or metallocene/organo-metal catalysts, not a Cr(III) diketonate/carboxylate.

That gap is what keeps the claims out of § 102 and pushes the real fight into § 103 — which is exactly the posture the prior Obviousness section already reached. The single highest-value reference on the page, US 3,953,413, is described in detail immediately below because it comes closest.

---

Tier 1 — The closest references on the face of the patent (read these first)

1. US 3,953,413 A — Hwang et al. — issued 4/1976 (filing date not retrieved)

Full citation: U.S. Pat. No. 3,953,413 A, Hwang et al., "Polymerization of olefins with a chromium chelate catalyst" (issue date April 1976, per the '459 front page).
Source retrieved: https://patentimages.storage.googleapis.com/17/ef/96/e2517ded45e467/US3953413.pdf

Description (from the reference's own text, quoted):

• Catalysts "consist[ing] essentially of low-valent chromium surface species … dispersed and supported on at least one difficult to reduce inorganic oxide."
• The chromium source is "a chromium chelate of a beta-dicarbonyl compound of which chromium acetylacetonate is a good example," expressly stated to be "low valent with a valence of three as compared to the valence of six of the prior art chromium oxide-containing catalysts" — i.e. an explicit Cr(III) acetylacetonate teaching.
• The activation step is "thermal decomposition under a substantially oxygen free atmosphere, for example one that is inert such as nitrogen or reducing such as carbon monoxide," and "activation of the catalyst at elevated temperatures of preferably to about 850°–2000°F … accomplished either in a fluid bed maintained by the flow of non-oxidizing gas or in a stationary bed under high vacuum."
• Dispersion may be by "a conventional impregnation method using organic solvents such as toluene" or "by a more convenient method which calls for dry-blending of the chelate with the support and effecting the final dispersion during the initial stage of activation."
• Chromium level "may range from 0.05 to 5%."

§ 102 assessment — which claims it potentially anticipates:

• Claim 1 (process): NO — but it is the closest single reference on the page. It discloses the Cr(III) compound, the contact with a solid oxide, and the non-oxidizing-atmosphere/peak-temperature step (N₂ or CO, 850–2000 °F). It does not disclose that the solid oxide is "treated with an electron-withdrawing anion." Under § 102 that missing element is dispositive — a reference cannot anticipate a claim it does not disclose in every limitation. It is, however, the strongest § 103 primary reference on the page (Camp A), and it independently reads on the dry-mixing and inert/reducing-atmosphere dependent embodiments.
• Claim 9 (composition + co-catalyst): NO. It discloses no co-catalyst and no activator-support.
• Claim 13 (polymerization process): NO. Same deficiency, carried through.
• Product-by-properties claims (relaxation time, LCB, MWD figures): NO. The reference reports no relaxation time, no Janzen–Colby LCB value, and no Mz/Mw — the recited numerical boundaries find no counterpart.
• Watch item: Hwang also names beta-keto aldehydes/dialdehydes generally, which is broader than the Cr(III) 1,3-diketone genus recited in the dependent claims — but breadth of disclosure does not cure the missing activator-support element.

2. US 4,146,695 A — van de Leemput — issued 3/1979

Full citation: U.S. Pat. No. 4,146,695 A, van de Leemput (printed on the '459 front page in OCR form as "can de Leemput" — a scan artifact, not a different inventor; I am reporting it as printed and flagging the OCR).
Description: Stamicarbon-line chromium-chelate-on-inorganic-oxide olefin polymerization catalyst. This sits on the same inventor/assignee line identified in the prior Obviousness section as the Stamicarbon Cr(acac)₃/support family (cf. US 4,435,551 / US 4,504,592, which are not on the '459 front page and must be pulled separately — see "What to pull next").
§ 102 assessment: NO anticipation of any claim. Supplies Cr(III) chelate + untreated oxide support + organoaluminum co-catalyst, i.e. Camp A. No electron-withdrawing-anion-treated support.

3. EP 0 055 866 A2 — (Phillips) — published 7 July 1982 (per the "Also Published As" table: GB 2 090 157 A, 1982-07-07)

Full citation: European Patent Application EP 0 055 866 A2 (also published as GB 2090157 A / B; family includes CA 1172236 A and JP S57135808 A).
Source retrieved: Google Patents EP0055866A2 page, which lists US10858459B2 among its citing documents — confirming it is in this family's citation chain. It also appears in the PubChem citation list for US 10,246,528 B2.
Description: Believed to relate to silicon- and/or fluorine-treated alumina supports for chromium catalysts. I retrieved only the bibliographic/listing data; I did not retrieve or read the specification text. Treat the description as a lead, not a verified finding.
§ 102 assessment: Flagged as the single highest-value unverified reference on this page. If its specification discloses a fluorided alumina support bearing a chromium compound for olefin polymerization, then: (i) it discloses element (b) in a chromium context, which materially closes the Camp A/Camp B gap and is the strongest potential § 102(a)(1)/§ 103 combination on the page; and (ii) it would strengthen the primary obviousness ground. If, as expected, the chromium species is a chromium oxide/Cr(VI) species rather than a Cr(III) diketonate treated non-oxidatively, it remains a § 103-only reference and anticipates nothing. Pull and read this before relying on any § 102 position. Note also the OCR-ambiguous sibling strings "EP 0 056 157 B1" / "EP 0 166 157 B1" reported in the earlier Obviousness section — I cannot confirm which of these is the correct number from the data retrieved, so any of them should be checked literally.

---

Tier 2 — Activator-support art cited on the face of the patent (supplies element (b) only)

Note on the "incorporated by reference" trap. US 7,294,599, US 7,601,665, US 7,884,163 and US 8,309,485 are expressly incorporated by reference into the '459 specification as the definitional source for "activator-supports." For § 102 purposes an incorporation by reference can supply a missing limitation — but only if the incorporated document itself discloses that limitation. None of these four discloses a Cr(III) diketonate or carboxylate deposited on the activator-support and heat-treated non-oxidatively. Incorporation by reference therefore does not create anticipation here; it does, however, mean the full text of all four is fair game and must be searched, because any Cr(III) example buried in them would be a § 102(a)(1) killer.

---

Tier 3 — Co-catalyst and metallocene art (supplies dependent-claim elements)

Structural point worth preserving: the metallocene-dependent claims (dual-component/bimodal MWD, Zr:Cr ratios) are not anticipated by any metallocene reference, because a metallocene reference necessarily omits the supported chromium (III) component, and they are not anticipated by any chromium reference, because those omit the metallocene. The only way to reach those claims is § 103 on a "combine two known catalyst types on a shared activator-support" rationale.

---

Tier 4 — Polymerization-process and reactor art (cited for context, not catalyst chemistry)

None of these discloses a chromium (III) compound, an activator-support, or the non-oxidizing treatment step. They cannot anticipate. Their only relevance is that they define the reactor and polymerization conditions the claims presume, so a § 103 combination using them as the "process context" reference is easy to assemble but proves nothing about the catalyst chemistry.

---

Tier 5 — Remaining U.S. citations on the front page (cataloged, no independent § 102 reach)

The following appear in the "(56) References Cited" U.S. sub-list and were cataloged but cannot anticipate on their own, for the uniform reason that they belong to Camp A or Camp B and not both:

US 2,951,816 (Hogan et al., 9/1960 — the foundational Phillips silica-supported chromium oxide catalyst; note this is Cr(VI), the very system the '459 patent distinguishes), 3,953,413 (see Tier 1), 4,788,171 (Klendworth, 11/1988 — content not independently verified; pull before relying on it, Klendworth is a Quantum/USI chromium-catalyst chemist), 4,803,253 (McDaniel et al., 2/1989), 5,001,204 (Klendworth et al., 3/1991 — same caution as 4,788,171), 5,401,820 (McDaniel et al., 3/1995), 6,011,127 (Monoi et al., 1/2000), 6,096,679 (Lonfils et al., 8/2000), 6,300,271 (McDaniel et al., 10/2001), 6,316,553 (McDaniel et al., 11/2001), 6,329,476 (Martin et al., 12/2001), 6,355,594 (McDaniel et al., 3/2002), 6,376,415 (McDaniel et al., 4/2002), 6,388,017 (McDaniel et al., 5/2002), 6,391,816 (McDaniel et al., 5/2002), 6,395,666 (McDaniel et al., 5/2002), 6,667,274 (Hawley et al., 12/2003), 6,831,141 (McDaniel et al., 12/2004), 7,163,906 (McDaniel et al., 1/2007), 7,312,283 (see Tier 3), 8,114,946 (cited in the spec only as the LCB-determination methodology reference — a test-method citation, not catalyst art).

Two mechanical flags on this sub-list:

• US 2,951,816 is attributed on the '459 front page to "Hogan et al." but on the sibling US 10,662,266 front page the same number is attributed to "Banks" (OCR). I am reporting both as printed rather than reconciling; the "Hogan & Banks" Phillips attribution is the historically correct one.
• The sibling '266 OCR renders several numbers defectively (e.g. "4,588,799" for 4,588,790; "4,805,561" for 4,808,561; "5,730,920" for 5,739,220; "5,565,175 Hutowy" for Hottovy; "4,501,885 Shett" for Sherk). Use the '459 list, not the '266 OCR, as the citation set of record.

---

Foreign patent documents on the face of the patent

I retrieved these four WO numbers only as bibliographic entries in the family citation lists; I did not retrieve or read their specifications, so I am not asserting anything about their content.

---

Non-patent literature (partially retrieved — flagged as incomplete)

The "Other Publications" sub-block of the '459 front page was not fully retrieved. The NPL items established in the prior Obviousness section as being in this family's IDS, and which I therefore carry forward without re-verification in this pass, are:

• McDaniel, M. P., Advances in Catalysis, 2010, Chapter 3 — expressly cited in the '459 specification (as "Chapter 3") for the Cr(VI) baseline behaviors the patent distinguishes, including the ~10 ppm Al-alkyl deactivation ceiling and the Mw-falls-with-rising-activation-temperature trend. This is the patent's own teaching-away / comparative reference. § 102: none — it does not disclose the claimed Cr(III) system; it is the § 103 backdrop.
• Coutinho et al., Polymer Bulletin 40 (1998) 695–700 — Cr(acac)₃/methylaluminoxane ethylene polymerization. § 102: none — no activator-support, no non-oxidizing-treatment step recited as such.
• Gaspar & Dieguez, Appl. Catal. A 227 (2002) 241; Weckhuysen et al., Chem. Rev. 96 (1996) 3327 — Cr precursor speciation incl. acetylacetonate on SiO₂; CO reduction to Cr²⁺. § 102: none — § 103/§ 112 background.
• Janzen & Colby, J. Mol. Struct. 485/486 (1999) 569–584 — the LCB calculation method the patent uses. Test methodology only.

I am deliberately not enumerating further NPL entries, because I did not retrieve the complete "Other Publications" list and will not supplement it from memory.

---

§ 102 summary matrix — per claim group

---

What to pull next (ranked, before any § 102 or § 103 position is filed)

1. EP 0 055 866 A2 — the fluorine/silicon-treated alumina Chromium support application. If it discloses a fluorided alumina + chromium catalyst, it is the strongest reference on the page and the only cited document with a realistic shot at closing the Camp A/Camp B gap. Also check the OCR-ambiguous "EP 0 056 157 B1" / "EP 0 166 157 B1" strings literally.
2. US 4,788,171 and US 5,001,204 (Klendworth) — chromium-catalyst chemist with a Quantum/USI lineage; content unverified here and possibly relevant to element (a).
3. The four incorporated-by-reference activator-support patents in full (US 7,294,599; US 7,601,665; US 7,884,163; US 8,309,485) — search each specifically for any Cr(III) acetylacetonate / diketonate / carboxylate example. Incorporation by reference makes anything found there available against the '459 claims.
4. US 4,435,551 and US 4,504,592 (van de Leemput, Stamicarbon) — flagged in the prior Obviousness section as the strongest § 103 primaries. Note: these two numbers do NOT appear on the '459 front page (only their sibling US 4,146,695 does). They are still § 102(a)(1) art and are the primary obviousness references; pull them as prior art even though the patent did not cite them.
5. The complete "Other Publications" sub-block of the '459 front page — I could not retrieve it in full, and it is the one part of the citation set of record that remains genuinely unenumerated.
6. US 3,953,413's filing date and its Examiner citation status — the front-page date I have is the 4/1976 issue date; the filing date was not retrieved.

Explicit non-findings I am not papering over: I did not retrieve the complete foreign sub-list, did not retrieve the complete NPL sub-list, did not verify the content of EP 0 055 866 A2 or the WO documents, and did not verify the verbatim granted claims of US 10,858,459. Nothing in this section contradicts the earlier Patent Summary, Litigation, PTAB, Assignment, or Obviousness sections; the one open discrepancy carried forward unchanged is the 2014-01-08 vs. 2014-01-09 priority-date variance, which is immaterial to every § 102 conclusion above because all cited art predates 2014 by at least a decade.

I'll ground this analysis with a few targeted verification searches on the key references before building the §103 combinations.

Let me verify two references that materially affect the obviousness picture.

Obviousness Analysis — US 10,858,459 B2 under 35 U.S.C. § 103

Building on the Prior Art section. The prior-art section ranked WO 1993/002111 A1 (Neste Oy) as the closest §102 reference and flagged Coutinho et al. (1998) as the key NPL reference on the Cr(III)/alkylaluminum combination. This section takes those as given and does not repeat their descriptions. Where I depart from that section, I say so explicitly — and I do depart on one point (see §7).

Two new references surfaced during this pass that materially change the §103 picture. I flag them up front because they were not in the prior-art section:

---

1. Framework and the claims actually being analyzed

Governing law. The application was filed 2020-04-03, after 2013-03-16, so AIA §§ 102/103 apply. Because the patent claims priority to 2014-01-09, the presumptive critical date for prior art is 2014-01-09, and AIA § 102(b)(1)(A) gives a one-year grace period only for inventor-originating disclosures. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), governs the motivation/expectation analysis; Graham v. John Deere Co., 383 U.S. 1 (1966), supplies the four factual inquiries.

Claims analyzed — express caveat. As the prior-art section noted, the verbatim granted claim set of the '459 patent was not retrievable. However, this pass located verbatim claim language from the sibling US 10,662,266 B2 (a continuation in the same family, filed from the same specification), which is the best available proxy:

• Claim 1 (composition): "a supported chromium catalyst comprising (a) a chromium (III) compound, or a derivative thereof; and (b) an activator-support comprising a solid oxide treated with an electron-withdrawing anion; and a co-catalyst."
• Claim 8 (process): "(i) combining a chromium (III) compound with an activator-support comprising a solid oxide treated with an electron-withdrawing anion to form a mixture; and (ii) subjecting the mixture to a non-oxidizing atmosphere at a peak temperature to produce the supported chromium catalyst."
• Dependents: 9 (peak 25–600 °C); 10 (inert atmosphere); 11 (dry-mix/sublime or solvent-mix/solvent-removal); 12 (Cr(AcAc)₃ + sulfated alumina / fluorided silica-alumina / fluorided silica-coated alumina); 13 (0.25–5 wt% Cr; 2–15 wt% anion); 14 (100–350 °C + inert); 17 (supported catalyst produced by the process of claim 8); 18 (variant process).
• Source: https://patentimages.storage.googleapis.com/4b/f0/27/2e73955ff8b86b/US10662266.pdf

Numbering hazard for a brief: the '266 grant numbers the process claim 8; the '459's process claim is, per the earlier section, claim 1. Do not cross-cite claim numbers between the two patents.

---

2. Element breakdown

¹ US 7,294,599; 7,601,665; 7,884,163; 8,309,485 (all expressly incorporated by reference into the '459 for this purpose); plus US 4,803,253 / EP 0 055 866 A2 (Phillips fluorided-alumina chromium catalyst), which are on the face of the '459 as cited references.

The single missing element across the whole field is (b) — the electron-withdrawing-anion-treated solid oxide. That is what the obviousness case must supply, and the specification's own data make it easy: the patentee's Examples 5–7 (fluorided/sulfated supports, 1270–2167 g/g/h) versus Examples 1–4 (untreated silica, alumina, aluminophosphate, silica-coated alumina, 56–150 g/g/h) establish a ~10–40× activity enhancement attributable solely to the anion treatment. That is an express teaching in the patentee's own specification that the anion-treated support is a known, predictable performance enhancer for a Cr catalyst.

---

3. The combinations

Combination 1 (primary) — Stamicarbon art + Phillips/CPChem activator-support art

References: DE 2831581 C2 (Stamicarbon B.V., filed 1978-07-18; https://www.freepatentsonline.com/DE2831581C2.html); EP 0 072 076 A1 (van de Leemput & Nooijen, Stamicarbon; https://trade.patenthub.cn/cpc/patent-99934-EP0072076A1-...); US 4,504,592 (https://patents.justia.com/patent/[4504592](/patent/4504592)); US 4,435,551 (https://patents.justia.com/patent/[4435551](/patent/4435551)); in view of US 7,294,599 / 7,601,665 / 7,884,163 / 8,309,485 and US 4,803,253 / EP 0 055 866 A2.

What Stamicarbon discloses (verbatim from the sources I retrieved):

• A chromium 1,3-diketo compound (Cr(AcAc)₃ expressly named) reacted with a Group II/III organometallic (TIBA expressly used), the reaction product applied to an inert inorganic support (silica preferred), and
• "heating the product after deposition on an inorganic support in a non-reducing atmosphere" at 200–1200 °C, then "combining the resulting product with an organometallic compound of an element of Group II or Group III," to polymerize a C₂–C₈ 1-alkene;
• Typical worked example: "a complex of Cr(acac)₃ and TIBA … 24 g silica support is predried … the Cr(acac)₃/TIBA complex … added dropwise … catalyst thus prepared is activated by heating for 8 hours at 900 °C";
• And, critically, the express suggestion: "If desired, during or after preparation the silica can in a known manner be provided with other components, such as, for example, fluorine."

Motivation to combine — three independent, documented rationales:

1. Express lead in the primary reference. The Stamicarbon disclosure itself points to fluorine as a support additive. KSR teaches that an express suggestion in the art, however general, supports obviousness. This is not hindsight reconstruction; it is the reference naming the exact claimed modification.
2. Known, art-recognized function. The activator-support patents (and their Phillips predecessors US 4,803,253 and EP 0 055 866 A2, both of record) teach that treating a solid oxide with fluoride or sulfate raises its Lewis/Brønsted acidity and markedly increases Cr polymerization activity. Where a technique is known to improve the same property in the same class of catalyst, its application is obvious. KSR, 550 U.S. at 417.
3. Same field, same problem, same elements. Both families are supported-chromium ethylene polymerization catalysts seeking broad-MWD HDPE with good activity; the Stamicarbon references themselves discuss MWD control, co-catalyst addition, hydrogen as a molecular-weight regulator, and gas-phase/slurry operation.

Reasonable expectation of success: High. The anion-treated support is a support swap, not a mechanism change; the Cr precursor, the thermal treatment step, and the cocatalyst are unchanged. The patentee's own Example 5 (fluorided silica-coated alumina, 2167 g/g/h) versus Example 4 (un-fluorided silica-coated alumina, 141 g/g/h) demonstrates that the swap works, and does so with a plain N₂-treated Cr(AcAc)₃ catalyst.

Claims swept in: claim 1 (composition); claim 8 (process); 9 (peak temperature — Stamicarbon 200–1200 °C overlaps 25–600 °C); 10 (inert — Stamicarbon lists N₂, CO₂, noble gases); 11 (the "sublime or vaporize" alternative is separately met by WO 93/02111, and the "solvent-mix, remove solvent" alternative is literally what Stamicarbon does); 12 (Cr(AcAc)₃ + fluorided silica-alumina/silica-coated alumina/sulfated alumina); 13 (Cr loading 0.25–5 wt% — Stamicarbon teaches 0.01–10 wt%); 14 (100–350 °C + inert); 17 (product-by-process).

---

Combination 2 — WO 1993/002111 (Neste Oy) + activator-support art

References: WO 1993/002111 A1 (https://patentimages.storage.googleapis.com/f1/5d/74/85cde820ba7b1b/WO1993002111A1.pdf); EP 0 438 132 A2 (Neste, same program; https://patents.google.com/patent/EP0438132A2/en); in view of the activator-support patents.

The fit: WO 93/02111 vaporizes Cr(acac)₃ and chemisorbs it onto an inorganic oxide (silica, alumina, titania, zirconia, magnesia, and mixtures thereof), with "the reaction between the vapour of the catalytically active metal compound and the support … carried out in an inert gas atmosphere or, alternatively, at reduced pressure," at 160–500 °C, "1…4 h" reaction time. That is the recited step (ii) almost verbatim, including the range and the time period. The reference's support is untreated, so the only gap is element (b).

Motivation: Identical to Combination 1 — the anion-treated support is a known, art-recognized activity enhancer in this exact field, and the Neste reference is expressly directed to maximizing activity at low Cr loading ("the activity of a catalyst … even with a very low content of catalytic metal is as high as … conventional methods"). A POSA optimizing Neste's process would not need to look far.

Important limitation on this reference (this is where I part company slightly with the prior-art section). The Neste/EP 0 438 132 disclosure's final activation is in an oxidizing atmosphere at 400–1000 °C. If a petition relies on WO 93/02111 alone for the "non-oxidizing" step, the patentee will argue the reference teaches away: its activation step is precisely the Cr(VI)-forming calcination the '459 avoids. The reference is therefore stronger as a teaching of the vapor-deposition step and weaker as a teaching of "non-oxidizing at peak temperature." For that element, Stamicarbon (Combination 1) is the better anchor, because it expressly lists N₂ and noble gases as the non-reducing medium.

---

Combination 3 — Coutinho 1998 + Stamicarbon + activator-support art (composition and polymerization claims)

Reference: Coutinho et al., Polymer Bulletin 40(6), 695–700 (1998), DOI 10.1007/s002890050310 (https://link.springer.com/article/10.1007/s002890050310).

Coutinho expressly discloses Cr(acac)₃ activated by Al(C₂H₅)₃, Al(i-C₄H₉)₃, or MAO for ethylene polymerization, with the Al/Cr ratio, temperature, aging time and cocatalyst type varied, and the products characterized by SEC and DSC. This is the composition claim's (a) + co-catalyst elements, and the polymerization-process claim, in a single reference — in homogeneous form. (Note: the search text rendered TIBA inconsistently as "Al(i-C₅H₉)₃" in one abstract and "Tritsobutylaluminium (TIBA)" in the materials section; a petition should quote the PDF, not the abstract.)

Motivation to combine with a support: Heterogenizing a homogeneous Cr(acac)₃/AlR₃ system onto a supported activator is the single most obvious commercial move in this art — it is what makes the catalyst usable in slurry and gas-phase reactors, controls morphology, and avoids reactor fouling. The Stamicarbon references show the art had already done exactly that (Cr(acac)₃/TIBA deposited on silica), and the activator-support patents supply the anion-treated oxide.

The patentee's strongest counter to this combination is teaching away — see §4.

---

Combination 4 — The polymer claims (claim 16 / '459 claim 16-type) are obvious as inherent products of an obvious process

This is the most dangerous combination and, in my view, under-weighted in the prior-art section.

The claimed ethylene polymer is defined only by properties (Mw 300k–1M; Mw/Mn ≥ 50; relaxation time ≤ 100 s). Where a product claim is defined by properties and the process producing it is obvious or substantially identical to the prior art, the burden shifts to the patentee to show the prior-art product does not necessarily possess those properties. In re Best, 562 F.2d 1252 (CCPA 1977); In re Fitzgerald, 619 F.2d 67 (CCPA 1980). Product-by-process claims are treated the same way for §103 — the process steps are limiting for infringement but the patentability analysis turns on the product. In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985); MPEP § 2113.

The problem for the patentee is empirical, and it is in the patent itself. The specification's Table I reports, for Examples 1–4 — which use untreated silica, alumina, aluminophosphate, and un-fluorided silica-coated alumina — the following (columns as rendered in the Google Patents text; the last two columns are partly garbled and should be re-verified against the PDF at https://patentimages.storage.googleapis.com/b4/1b/f5/746c82f45e9a79/US10858459.pdf):

Every one of these comparative, non-fluorided, non-sulfated examples lands inside the claimed Mw window (300k–1M) and above the claimed Mw/Mn floor of 50. If the relaxation-time figures for these examples (which the OCR dropped) are also ≤ 100 s, then the claimed polymer is produced by a process using an ordinary solid oxide — and the polymer claim collapses onto Stamicarbon's Cr(acac)₃/TIBA-on-silica disclosure under In re Best. Even if their relaxation times exceed 100 s, the patentee is left arguing that a property the specification ties to the Cr(III) precursor (not to the anion) somehow confers patentability. See §8, item 3, for the written-description corollary.

Additional polymer-claim art: US 2013/0137839 A1 (Yu et al., "Long Chain Branched Polymers and Methods of Making Same") is directed to LCB control in the same field and is of record, and US 8,501,882 B2 / US 8,829,125 B2 (Ding) are directed to controlling polymer properties with hydrogen — which is precisely the hydrogen-sensitivity behavior the '459 asserts as unexpected.

---

Combination 5 — Hydrogen-sensitivity claims

References: US 8,501,882 B2 (Ding, 2013-08-06) and US 8,829,125 B2 (Ding, 2014-09-09), both expressly flagged on the '459 face as examiner-cited, both titled "Use of Hydrogen and an Organozinc Compound for Polymerization and Polymer Property Control," in view of Coutinho and Stamicarbon.

If any claim recites hydrogen addition or a hydrogen:mole-olefin ratio, the motivation is essentially definitional — hydrogen is the universal chain-transfer agent for melt-index control in olefin polymerization, and both the Stamicarbon and Coutinho references expressly discuss hydrogen and organometallic modifiers for molecular-weight control. The difficult claims for the patentee are those where sensitivity or a magnitude of MI increase is required; there, the patentee has real data (Table III: "a dramatic increase in melt index as hydrogen is added," versus Cr(VI)/silica which is "largely unaffected"), and a nexus argument is available.

---

Combination 6 — Dual-catalyst / bimodal claims

If any claim requires a metallocene or a bimodal MWD, the art of record (US 7,026,494; 7,041,617; 7,199,073; 7,226,886; 7,312,283; 7,517,939; 7,619,047; 7,863,210; 7,919,639; 8,012,900; 8,080,681 — all cited in the '459 for exactly this purpose) makes the combination obvious as a matter of combining known catalysts. Note, however, the '459's stated advantage — that a single activator-support activates both the Cr and the metallocene Zr in the absence of MAO — may be a genuine, non-obvious functional result if supported by data.

---

4. Teaching away — the patentee's best §103 defense

The patentee has an unusually strong teaching-away narrative, and any petition must neutralize it before institution.

The patentee's specification confronts this head-on: "catalyst compositions of the present invention can tolerate much higher levels of co-catalyst than catalyst systems employing Cr(VI)"; "unlike typical Cr(VI) catalysts"; FIG. 11. If those data are accurate and reproducible, In re Soni / Rambus support non-obviousness of the co-catalyst-tolerance-dependent claims.

The petitioner's rebuttal should be that (i) teaching away requires that the reference "criticize, discredit, or otherwise discourage" the claimed solution — Coutinho's and EP 0 861 854's failure with TIBA is criticism of an unsupported homogeneous Cr(acac)₃ system, not of a Cr(III)/anion-treated-support system, and the whole premise of Combination 1 is that the support changes the outcome; (ii) Stamicarbon did use TIBA with supported Cr(acac)₃ and reported it worked; and (iii) the '459's independent claims contain no co-catalyst-ratio lower bound — the high-Al/Cr and activity limitations live only in dependent claims (e.g., '266 claim 4), so the broad independent claims are unaffected by the teaching-away evidence.

---

5. Objective indicia of non-obviousness (secondary considerations)

The '459 asserts six unexpected results. Under WBIP / Volvo, each needs nexus to the claimed subject matter and the showing must be commensurate in scope with the claims.

Patentee's exposure: results 1–4 are all framed against Cr(VI) comparators. Under KSR, the "closest prior art" is not necessarily Cr(VI) — it is the Stamicarbon/WO 93/02111 Cr(III)-based art. None of the six asserted results is expressly compared against a Cr(III) on plain silica control, even though the specification's own Examples 1–4 provide exactly that control. That is the single biggest hole in the objective-indicia case, and it is the hole a petitioner should aim at.

---

6. Claim-by-claim vulnerability ranking

Note the two upstream sections: the patent is untested at the PTAB (zero AIA proceedings) and I found no litigation. Practically, that means there is no Board construction of "non-oxidizing atmosphere," "activator-support," or "relaxation time" to build on — the construction work in §2 is the petitioner's to do, and it is the highest-value pre-petition task.

---

7. Flagged contradiction with the prior-art section — read this

The prior-art section treats the long list of examiner-cited references as "predominantly background/incorporation-by-reference." I agree with that assessment for most of them. But it also lists among the cited U.S. documents US 4,146,695 (3/27/1979, van de Leemput) — which, on the identification given, is a Stamicarbon/van de Leemput patent.

If US 4,146,695 is in the Stamicarbon family I identified above (DE 2831581 / EP 0 072 076 / US 4,504,592 / US 4,435,551, all filed 1977–1978 and sharing the Cr(acac)₃ + organoaluminum + non-reducing-heat-treatment disclosure), then the primary §103 anchor in this analysis is already on the face of the '459 as a cited reference — and the examiner cited it without apparently applying it. That is a materially different posture from "uncited art," and it matters for § 325(d): a petitioner relying on US 4,146,695 will have to address the Board's discretion to deny under § 325(d) ("the same or substantially the same art previously presented to the Office"). The remedy is to lead with DE 2831581 C2 and EP 0 072 076 A1 (foreign counterparts that are not in the '459's "Foreign Patent Documents" list — that list contains only EP 0 055 866; WO 93/02111; WO 99/60033; WO 2005/107943; WO 2006/052232) and to use US 4,146,695 as corroboration rather than as the primary reference.

I could not confirm that US 4,146,695 and DE 2831581 are in the same family — this is an inference from inventor name (van de Leemput), assignee (Stamicarbon), subject matter, and date proximity. Verify with the EPO/Espacenet family view for DE 2831581 and US 4,146,695 before relying on it.

---

8. The priority-date trap (a distinct and serious exposure)

This is not a §103 combination, but it changes which references count as §103 art, so it belongs here.

McDaniel, M.P. & Clear, K.S., "Ethylene polymerization by Cr(III) salts on acidic carriers," Applied Catalysis A: General 527 (2016) 116–126 is authored by two of the three named inventors and describes, in the open literature: Cr(AcAc)₃ dry-mixed onto fluorided silica-alumina and fluorided silica-coated alumina, heated in a nitrogen fluidized bed at 250 °C for one hour, with TIBA as the preferred cocatalyst; activity vs. cocatalyst concentration; MW/MWD by support calcination temperature; LCB/low-shear viscosity analysis. That is the invention, element for element.

• On the 2014-01-09 priority date, this paper is a post-filing publication by the inventors and is not prior art at all.
• If any claim's effective filing date is instead 2020-04-03 — because the claim lacks § 112 written-description support in the 2014-01-09 priority application — then the 2016 paper becomes § 102(a)(1) prior art, and the § 102(b)(1)(A) grace period does not save it (four years elapse between the paper and the 2020 filing; the grace period is one year). The same analysis would apply to the family's own 2015/2019 pre-grant publications, subject to the § 102(b)(2)(C) common-ownership exception for the § 102(a)(2) side.
• The practical test: every claim limitation must have written-description and enablement support in the 2014-01-09 application (application 14/151,032). Limitations most at risk are the narrow polymer property ranges (relaxation time ≤ 100 s; specific LCB values), the specific Mw/Mn thresholds, and any claim language drafted during the 2016–2019 prosecution.

The earlier sections flag that the '459 is a continuation (of US 10,662,266, itself a division of US 10,246,528) and note the missing verbatim claim set. Priority-chain verification against the 2014 specification is, in my assessment, the single highest-value defensive work item on this patent — it either removes or unlocks the most on-point reference in the entire field.

---

9. § 112 fallback (brief, because it feeds §103)

Three limitations are worth a construction challenge in parallel with the §103 case:

1. "relaxation time" — defined in the specification only by reference to the Carreau-Yasuda method (with the underlying NPL being Hieber & Chiang, Rheol. Acta 28, 321 (1989) and Polym. Eng. Sci. 32, 931 (1992), and Bird et al.). Whether the claim appends a units/method limitation or reads on a bare numerical value is a genuine indefiniteness question under Nautilus.
2. "a derivative thereof" of the chromium (III) compound — the specification expressly uses this to cover species that "may lose one ligand (or more ligands)" during preparation. That is an unbounded, purely functional recitation of the chromium moiety.
3. "about" modifying every numerical endpoint in the polymer claims. Under Honeywell v. ITC and Niazi, "about" is not automatically indefinite, but combined with a ranges-within-ranges drafting style it enlarges the claim to the prior art's doorstep.

---

10. Bottom line

1. The claims are, in my assessment, vulnerable to §103. The field supplies every element: Cr(III) 1,3-diketonate + organoaluminum on a support, heated in a non-reducing atmosphere, used to polymerize ethylene (Stamicarbon: DE 2831581 C2; EP 0 072 076 A1; US 4,504,592; US 4,435,551; and, in vapor-deposition form, WO 93/02111 (Neste) and Coutinho 1998), plus the electron-withdrawing-anion-treated solid oxide, which is a known, art-recognized activity enhancer for chromium catalysts and is the subject of patents expressly incorporated into the '459 itself (US 7,294,599; 7,601,665; 7,884,163; 8,309,485; US 4,803,253; EP 0 055 866).

2. The best single combination is Stamicarbon + CPChem/Phillips activator-support art, because Stamicarbon supplies both the "non-reducing atmosphere at elevated temperature" step and an express fluorine suggestion for the silica support — which largely defeats the hindsight objection.

3. The strongest §103 attack is not on the process claim but on the property-defined polymer claims. The specification's own Examples 1–4 — on untreated silica, alumina, aluminophosphate, and un-fluorided silica-coated alumina — report Mw of 468–801 kg/mol and Mw/Mn of 68.6–84.2, i.e., inside the claimed windows without any activator-support. Under In re Best, that is close to a self-inflicted prima facie case of obviousness.

4. The patentee's real defenses are (i) teaching away on co-catalyst loading (Coutinho; EP 0 861 854; McDaniel 2010 — all showing organoaluminum kills or barely activates Cr systems at high Al/Cr) and (ii) low LCB / short relaxation time (FIGS. 7–8), which is the best-supported and best-quantified objective indicium. Both defenses are strongest against dependent claims and weakest against the broad independent claims, none of which recite a co-catalyst ratio, an LCB value, or a relaxation time.

5. Two things I could not verify and would not assert: (a) that US 4,146,695 is the US counterpart of DE 2831581 (§7); (b) the verbatim granted claim set of the '459 — the analysis above uses the sibling US 10,662,266 B2 claim language as the proxy, per the earlier section's caveat. Confirm both, plus the Table I column alignment for Examples 1–4, against the granted PDF.

Primary sources used in this section: https://patentimages.storage.googleapis.com/4b/f0/27/2e73955ff8b86b/US10662266.pdf (verbatim sibling claims); https://patentimages.storage.googleapis.com/b4/1b/f5/746c82f45e9a79/US10858459.pdf (specification and tables); https://www.freepatentsonline.com/DE2831581C2.html (Stamicarbon); https://patents.justia.com/patent/4504592 and https://patents.justia.com/patent/4435551 (Stamicarbon/van de Leemput); https://patentimages.storage.googleapis.com/f1/5d/74/85cde820ba7b1b/WO1993002111A1.pdf and https://patents.google.com/patent/EP0438132A2/en (Neste Oy); https://link.springer.com/article/10.1007/s002890050310 (Coutinho et al. 1998); https://patentimages.storage.googleapis.com/ab/74/3c/ceef7b81b329fb/EP0861854A1.pdf (Cr(III) amide/alumoxane); https://patents.google.com/patent/WO2015105738A2/en (family publication mirroring the '459 examples); https://patentimages.storage.googleapis.com/94/3c/0a/d24865ab44cbec/EP0166157A3.pdf and the EP 0 055 864/866 materials (Phillips/McDaniel fluorided-alumina supports).